• 154,692+ Medical Conferences
  • 285 Specialties
  • 11,299 Organizers
  • 156,527 Speakers
  • 159 Countries
  • 4,789 Cities
CME Conference Registrations Sold


Talazoparib Beneficial in Patients With Advanced Breast Cancer

Talazoparib Beneficial in Patients With Advanced Breast Cancer

Thu, Aug 16, 2018

WEDNESDAY, Aug. 15, 2018 (HealthDay News) -- Single-agent talazoparib provides significant benefit over standard chemotherapy for patients with advanced breast cancer and germline BRCA1/2 mutation, according to a study published online Aug. 15 in the New England Journal of Medicine.

Jennifer K. Litton, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a randomized phase 3 trial involving patients with advanced breast cancer and a germline BRCA1/2 mutation. Participants were randomized to receive talazoparib (287 patients) or standard single-agent therapy of the physician's choice (144 patients).

The researchers found that, compared with the standard therapy group, the talazoparib group had significantly longer median progression-free survival (8.6 versus 5.6 months; hazard ratio for disease progression or death, 0.54; 95 percent confidence interval, 0.41 to 0.71; P < 0.001). For death, the interim median hazard ratio was 0.76 (95 percent confidence interval, 0.55 to 1.06; P = 0.11). The talazoparib group had a higher objective response rate than the standard-therapy group (62.6 versus 27.2 percent; odds ratio, 5.0; 95 percent confidence interval, 2.9 to 8.8; P < 0.001). Overall, 55 and 38 percent of patients who received talazoparib and standard therapy, respectively, had hematologic grade 3 to 4 events. Outcomes reported by patients favored talazoparib, with significant overall improvements and significant delays noted in the time to clinically meaningful deterioration according to the global health status-quality-of-life and breast symptoms scales.

"Talazoparib resulted in a significantly longer progression-free survival than standard-of-care chemotherapy," the authors write.

The study was funded by the Pfizer company Medivation, which manufactures talazoparib.

Abstract/Full Text